A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. This patient ...
Jun 4, 2018
0
874
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University ...
May 7, 2018
0
26
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.
Apr 20, 2018
0
86
Doctors contemplating the best therapy for lung cancer patients may soon be able to predict the efficacy of a widely used lung cancer drug based on an imaging agent and a simple scan, according to the findings of a new clinical ...
Mar 7, 2018
0
152
A large team of researchers from the U.S., Spain and Australia has found that the efficacy of drugs for treating cancer aimed at targeting particular classes of mutations depends on the type of tumor tissue involved and the ...
A new UC San Francisco-led study challenges the dogma in oncology that most cancers are caused by one dominant "driver" mutation that can be treated in isolation with a single targeted drug. Instead, the new research finds ...
Nov 6, 2017
0
53
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...
Aug 22, 2017
0
42
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...
Aug 22, 2017
0
40
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature (a pattern of base swaps—e.g., Ts for Gs, Cs for As—throughout a genome) known in cancer genomics as "Signature ...
Aug 21, 2017
0
2
The average metastatic cancer has more genetic mutations than are seen in early stage tumors, a new study finds.
Aug 2, 2017
0
85
